Wave Life Sciences Ltd.

NasdaqGM:WVE Rapporto sulle azioni

Cap. di mercato: US$716.0m

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Wave Life Sciences Crescita futura

Future criteri di controllo 2/6

Si prevede che Wave Life Sciences aumenterà gli utili e i ricavi rispettivamente del 13.3% e 30.9% all'anno, mentre si prevede che l'EPS crescerà del 19.5% all'anno.

Informazioni chiave

13.3%

Tasso di crescita degli utili

19.5%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili23.6%
Tasso di crescita dei ricavi30.9%
Rendimento futuro del capitale proprion/a
Copertura analitica

Good

Ultimo aggiornamento26 Aug 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

We're Keeping An Eye On Wave Life Sciences' (NASDAQ:WVE) Cash Burn Rate

Aug 05
We're Keeping An Eye On Wave Life Sciences' (NASDAQ:WVE) Cash Burn Rate

Pinning Down Wave Life Sciences Ltd.'s (NASDAQ:WVE) P/S Is Difficult Right Now

Jun 25
Pinning Down Wave Life Sciences Ltd.'s (NASDAQ:WVE) P/S Is Difficult Right Now

We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth

Apr 09
We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth

Wave Life Sciences' Weighty Ambition: Carving Out Obesity Niche

Mar 09

Wave Life Sciences Ltd.'s (NASDAQ:WVE) 30% Price Boost Is Out Of Tune With Revenues

Mar 03
Wave Life Sciences Ltd.'s (NASDAQ:WVE) 30% Price Boost Is Out Of Tune With Revenues

We're Interested To See How Wave Life Sciences (NASDAQ:WVE) Uses Its Cash Hoard To Grow

Sep 13
We're Interested To See How Wave Life Sciences (NASDAQ:WVE) Uses Its Cash Hoard To Grow

Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Cut Their EPS Forecasts Substantially

May 08
Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Cut Their EPS Forecasts Substantially

Here's Why Wave Life Sciences (NASDAQ:WVE) Must Use Its Cash Wisely

Mar 30
Here's Why Wave Life Sciences (NASDAQ:WVE) Must Use Its Cash Wisely

Are Investors Undervaluing Wave Life Sciences Ltd. (NASDAQ:WVE) By 47%?

Jan 20
Are Investors Undervaluing Wave Life Sciences Ltd. (NASDAQ:WVE) By 47%?

Some Analysts Just Cut Their Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates

Nov 11
Some Analysts Just Cut Their Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates

Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?

Aug 12
Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?

Wave Life Sciences Q2 2022 Earnings Preview

Aug 10

Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?

Apr 21
Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?

Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Invest In Growth?

Jan 11
Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Invest In Growth?

We Think Wave Life Sciences (NASDAQ:WVE) Needs To Drive Business Growth Carefully

Sep 24
We Think Wave Life Sciences (NASDAQ:WVE) Needs To Drive Business Growth Carefully

What Does The Future Hold For Wave Life Sciences Ltd. (NASDAQ:WVE)? These Analysts Have Been Cutting Their Estimates

Aug 07
What Does The Future Hold For Wave Life Sciences Ltd. (NASDAQ:WVE)? These Analysts Have Been Cutting Their Estimates

Wave Life Sciences posts proof-of-concept data from genetic disorder study

Jun 02

Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Slashed This Year's Estimates

May 15
Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Slashed This Year's Estimates

Things Look Grim For Wave Life Sciences Ltd. (NASDAQ:WVE) After Today's Downgrade

Apr 02
Things Look Grim For Wave Life Sciences Ltd. (NASDAQ:WVE) After Today's Downgrade

Previsioni di crescita degli utili e dei ricavi

NasdaqGM:WVE - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/202689-138-188-1507
12/31/202556-156-147-1358
12/31/202462-138-138-1507
6/30/2024111-73-130-129N/A
3/31/2024113-62-139-138N/A
12/31/2023113-58-21-19N/A
9/30/202385-85-21-20N/A
6/30/202337-131-12-11N/A
3/31/202315-151-4-2N/A
12/31/20224-162-129-128N/A
9/30/20224-153-103-101N/A
6/30/202240-120-105-104N/A
3/31/202243-118-85-84N/A
12/31/202141-122-90-89N/A
9/30/202149-116-114-113N/A
6/30/202116-143-106-105N/A
3/31/202116-145-135-134N/A
12/31/202020-150-117-116N/A
9/30/202013-178-148-146N/A
6/30/202013-196-172-169N/A
3/31/202017-197-168-164N/A
12/31/201916-194-192-188N/A
9/30/201917-175-166-160N/A
6/30/201919-162-154-145N/A
3/31/201916-156-50-41N/A
12/31/201814-147-33-23N/A
9/30/201812-140-23-13N/A
6/30/20189-127-20-7N/A
3/31/20185-116N/A-99N/A
12/31/20174-102N/A-84N/A
9/30/20173-90N/A-74N/A
6/30/20173-82N/A-63N/A
3/31/20172-69N/A-42N/A
12/31/20161-56N/A-32N/A
9/30/20161-44N/A-25N/A
6/30/20160-31N/A-16N/A
3/31/20160-24N/A-18N/A
12/31/20150-19N/A-13N/A
9/30/20150-14N/A-7N/A
6/30/20150-10N/A-5N/A
3/31/20150-8N/A-5N/A
12/31/2014N/A-5N/A-4N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che WVE rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che WVE rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che WVE rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di WVE ( 30.9% all'anno) crescerà più rapidamente del mercato US ( 8.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di WVE ( 30.9% all'anno) crescerà più rapidamente di 20% all'anno.


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di WVE è previsto essere elevato tra 3 anni


Scoprire le aziende in crescita